Improved long-term suppression of HIV-1 replication with a triple-class multidrug regimen compared with standard of care antiretroviral therapy

AIDS

Volumn 16, Issue 5, 2002, Pages 719-725

  Van Praag, Rieneke M E ^a,b   Wit, Ferdinand W N M ^a,b   Jurriaans, Suzanne ^b   De Wolf, Frank ^b   Prins, Jan M ^a   Lange, Joep M A ^a,b  

^a Natl AIDS Therapy Evaluation Centre   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Antiretroviral therapy; HIV 1; Plasma HIV 1 RNA; Residual replication; Treatment intensification

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; LAMIVUDINE; NEVIRAPINE; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TREATMENT OUTCOME; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DIDEOXYNUCLEOSIDES; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; INDINAVIR; LAMIVUDINE; MIDDLE AGED; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TIME FACTORS; VIRAL LOAD; VIRUS REPLICATION; ZIDOVUDINE;

EID: 0037192582     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200203290-00007     Document Type: Article

References (37)

1. 3-Year suppression of HIV viremia with indinavir, zidovudine, and lamivudine
2. HIV-specific immune responses in subjects with high-level viral suppression with or without intermittent viremia treated for 3-5 years with HAART
3. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS Trial. Italy, the Netherlands, Canada and Australia Study
4. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
5. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
6. Presence of an inducible HIV-1 latent reservoir during highly active antlretroviral therapy
7. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection
8. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
9. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy
10. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy
11. Prevalence and predictive value of intermittent viremia with combination HIV therapy
12. Residual human immunodeficiency virus (HIV) type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years
13. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy
14. Time of initiation of antiretroviral therapy: Impact on HIV-1 viraemia. The Swiss HIV Cohort study
15. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy
16. Residual human immunodeficiency virus type 1 RNA in lymphoid tissue of patients with sustained plasma RNA of < 200 copies/ml
17. Persistence of episomal HIV-1 infection intermediates in patients on highly active antiretroviral therapy
18. Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure
19. Use of real-time PCR and molecular beacons to detect virus replication in human immunodeficiency virus type 1-infected individuals on prolonged effective antiretroviral therapy
20. Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy
21. Human immunodeficiency virus type 1 quasi species that rebound after discontinuation of highly active antiretroviral therapy are similar to the viral quasi species present before initiation of therapy
22. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy
23. Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy
24. Antiretroviral resistance during successful therapy of HIV type 1 infection
25. Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy
26. Alternative multi-drug regimen provides improved suppression of HIV-1 replication over triple therapy
27. Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir
28. The effect of treatment intensification in HIV-infection: A study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine
29. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection
30. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy
31. Antiretroviral intensification accelerates the decay of the latent reservoir of HIV-1 but does not eliminate ongoing virus replication
32. Antiretroviral drugs and the central nervous system
33. Antiretroviral drug concentrations in semen: Implications for sexual transmission of human immunodeficiency virus type 1
34. Antiretroviral drug concentrations in semen of HIV-1 infected men
35. Ongoing HIV dissemination during HAART
36. Human immunodeficiency virus type 1-infected persons with residual disease and virus reservoirs on suppressive highly active antiretroviral therapy can be stratified into relevant virologic and immunologic subgroups
37. High viral burden in the presence of major HIV-specific CD8(+) T cell expansions: Evidence for impaired CTL effector function